Research Article
Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer
Table 1
The characteristics of the analyzed patients in different groups.
| Characteristics | | | value | | % | | % |
| No. patients | 81 | | 56 | | | Gender (%) | | | | | | Male | 59 | 72.8% | 39 | 69.6% | 0.685 | Female | 22 | 27.2% | 17 | 30.4% | | (%) | | | | | | <59 | 35 | 43.2% | 21 | 37.5% | 0.505 | ≥59 | 46 | 56.8% | 35 | 62.5% | | PD-L1 (%) | | | | | | Positive | 14 | 17.3% | 11 | 19.6% | 0.227 | Negative | 14 | 17.3% | 15 | 26.8% | | Unknown | 53 | 65.4% | 30 | 53.6% | | ECOG PS (%) | | | | | | 0 | 26 | 32.1% | 10 | 17.9% | 0.508 | 1 | 43 | 53.1% | 43 | 76.8% | | ≥2 | 12 | 14.8% | 3 | 5.4% | | Tumor_location (%) | | | | | | Cardia | 25 | 30.9% | 14 | 25.0% | 0.448 | Body/fundus | 50 | 61.7% | 37 | 66.1% | | Pylorus | 6 | 7.4% | 5 | 8.9% | | Histological_differentiation (%) | | | | | | Poorly | 40 | 49.4% | 31 | 55.4% | 0.473 | Moderately | 37 | 45.7% | 23 | 41.1% | | Well | 4 | 4.9% | 2 | 3.6% | | No. of metastasis organs (%) | | | | | | <2 | 24 | 29.6% | 11 | 19.6% | 0.189 | ≥2 | 57 | 70.4% | 45 | 80.4% | | Liver metastasis (%) | | | | | | Yes | 49 | 60.5% | 31 | 55.4% | 0.55 | No | 32 | 39.5% | 25 | 44.6% | | Smoking_history (%) | | | | | | Smoke | 30 | 37.0% | 29 | 51.8% | 0.088 | Never smoked | 51 | 63.0% | 27 | 48.2% | | Drinking_history (%) | | | | | | Drink | 38 | 46.9% | 35 | 62.5% | 0.073 | Never drinked | 43 | 53.1% | 21 | 37.5% | | Anti-PD-1 treatment line (%) | | | | | | First line | 42 | 51.9% | 24 | 42.9% | 0.421 | Second line | 34 | 42.0% | 30 | 53.6% | | Third line | 5 | 6.2% | 2 | 3.6% | | Treatment type (%) | | | | | | Anti-PD-1 monotherapy | 8 | 9.9% | 7 | 12.5% | 0.741 | Combination therapy | | | | | | Anti-PD-1 plus chemotherapy | 55 | 67.9% | 37 | 66.1% | | Anti-PD-1 plus antiangiogenic therapy | 18 | 22.2% | 12 | 21.4% | |
|
|
ECOG PS: Eastern Cooperative Oncology Group Performance Status; PD-L1: programmed death ligand-1.
|